达沙替尼

C₂₂H₂₆ClN₇O₂S

488.01

MFCD11046566

Dasatinib has been used:

• as a protein kinase inhibitor to study its effects on macrophage polarization, lipogenesis, western diet-induced progression of simple steatosis into steatohepatitis (NASH), and liver fibrosis in mice
• as an SRC tyrosine kinase inhibitor to study its effects on hepatocellular carcinoma cells
• as a tyrosine kinase inhibitor to study its effects on autophagy in neuronal cells

Dasatinib is a thiazole-carboxamide compound that inhibits a broad spectrum of protein kinases such as breakpoint cluster region-tyrosine protein kinase ABL (Bcr-Abl), Btk family members, platelet-derived growth factor receptor α/β (PDGFR-α/β), and ephrin receptor kinase. It also inhibits Src-family kinases such as SRC tyrosine kinase, and lymphocyte-specific protein kinase (LCK). Dasatinib exhibits certain effects on hematopoietic cells like suppressing natural killer cell toxicity, inhibiting T lymphocytes activation and proliferation, and influencing platelet activation. It is also studied in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

≥98% (HPLC)

powder

white to beige

DMSO: 2 mg/mL, clear

−20℃

CC1=NC(NC2=NC=C(C(NC3=C(C=CC=C3Cl)C)=O)S2)=CC(N4CCN(CC4)CCO)=N1

1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

human ... ABL1(25), BLK(640), EPHA2(1969), FGR(2268), FRK(2444), FYN(2534), HCK(3055), KIT(3815), LCK(3932), LYN(4067), PDGFRB(5159), SRC(6714), SRMS(6725), YES1(7525)

GHS05,GHS08,GHS09

Danger

H315 - H318 - H351 - H361fd - H372 - H410

P202 - P273 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 2 - Skin Irrit. 2 - STOT RE 1

Gastro-intestinal system

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK 3